Globus Medical Investors Should Focus on This

By Tamara Parker • Wednesday, November 29 14:00 • Permanent Link

Is it worth buying Globus Medical stock at a price of $45.14? If this question is on your mind, make sure to check out the fundamentals of this None mid-cap company:

Globus Medical has logged a -39.0% 52 week change, compared to 13.0% for the S&P 500
GMED has an average analyst rating of hold and is -29.0% away from its mean target price of $63.58 per share
Its trailing earnings per share (EPS) is $1.47, which brings its trailing Price to Earnings (P/E) ratio to 30.7. The Health Care sector's average P/E ratio is None
The company's forward earnings per share (EPS) is $2.73 and its forward P/E ratio is 16.5
The company has a Price to Book (P/B) ratio of 1.52 in contrast to the Health Care sector's average P/B ratio is None
GMED has reported YOY quarterly earnings growth of -98.1% and gross profit margins of 0.7%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.